Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats

被引:68
作者
Choi, SuJean
DiSilvio, Briana
Unangst, JayLynn
Fernstrom, John D.
机构
[1] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Sch Med, Dept Neurosci, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Sch Med, Dept Psychol, Pittsburgh, PA 15213 USA
关键词
olanzapine; clozapine; rat; body weight; food intake; pharmacokinetics;
D O I
10.1016/j.lfs.2007.08.009
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Many antipsychotics cause weight gain in humans, but usually not in rats, when injected once or twice daily. Since blood antipsychotic half-lives are short in rats, compared to humans, chronic administration by constant infusion may be necessary to see consistent weight gain in rats. Male and female rats were implanted with mini-pumps for constant infusion of olanzapine (5 mg/kg/day), clozapine (10 mg/kg/day) or vehicle for 11 days. Food intake and body weight were measured; blood drug levels were measured by HPLC. Olanzapine increased food intake and body weight in female, but not male rats. Serum olanzapine concentrations were 30-35 ng/ml. Clozapine had no effect on food intake or body weight in female or male rats. Serum clozapine concentrations were about 75 ng/ml. Single-dose pharmacokinetic analysis revealed a serum terminal half-life of 1.2-1.5 h for each drug, with no sex differences. Despite the fact that olanzapine and clozapine promote weight gain in humans, these drugs appear to have minimal effects on body weight and food intake in rats, except for a modest effect of olanzapine in female rats, even though therapeutic levels of olanzapine are achieved in serum during chronic infusion. Hence, the rapid clearance of drug following single administration in previous studies cannot explain the weak or absent effects of antipsychotics on weight gain in this species. The rat thus appears to be an inadequate model of weight gain produced by some antipsychotics in humans. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1024 / 1030
页数:7
相关论文
共 30 条
[1]   Second-generation antipsychotics - Is there evidence for sex differences in pharmacokinetic and adverse effect profiles? [J].
Aichhorn, Wolfgang ;
Whitworth, Alexandra B. ;
Weiss, Elisabeth M. ;
Marksteiner, Josef .
DRUG SAFETY, 2006, 29 (07) :587-598
[2]   Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents [J].
Albaugh, Vance L. ;
Henry, Cathy R. ;
Bello, Nicholas T. ;
Hajnal, Andras ;
Lynch, Susan L. ;
Halle, Beth ;
Lynch, Christopher J. .
OBESITY, 2006, 14 (01) :36-51
[3]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[4]  
Allison DB, 2001, J CLIN PSYCHIAT, V62, P22
[5]   An animal model of antipsychotic-induced weight gain [J].
Arjona, AA ;
Zhang, SX ;
Adamson, B ;
Wurtman, RJ .
BEHAVIOURAL BRAIN RESEARCH, 2004, 152 (01) :121-127
[6]   TISSUE CONCENTRATIONS OF CLOZAPINE AND ITS METABOLITES IN THE RAT [J].
BALDESSARINI, RJ ;
CENTORRINO, F ;
FLOOD, JG ;
VOLPICELLI, SA ;
HUSTONLYONS, D ;
COHEN, BM .
NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) :117-124
[7]   EFFECTS OF LONG-TERM ADMINISTRATION OF CLOZAPINE ON BODY-WEIGHT AND FOOD-INTAKE IN RATS [J].
BAPTISTA, T ;
MATA, A ;
TENEUD, L ;
DEQUIJADA, M ;
HAN, HW ;
HERNANDEZ, L .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 45 (01) :51-54
[8]   Mechanism of the neuroleptic-induced obesity in female rats [J].
Baptista, T ;
Contreras, Q ;
Teneud, L ;
Albornoz, MA ;
Acosta, A ;
Paez, X ;
de Quijada, M ;
Lacruz, A ;
Hernandez, L .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1998, 22 (01) :187-198
[9]   LONG-TERM ADMINISTRATION OF SOME ANTIPSYCHOTIC-DRUGS INCREASES BODY-WEIGHT AND FEEDING IN RATS - ARE D2 DOPAMINE-RECEPTORS INVOLVED [J].
BAPTISTA, T ;
PARADA, M ;
HERNANDEZ, L .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 27 (03) :399-405
[10]   Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone [J].
Basson, BR ;
Kinon, BJ ;
Taylor, CC ;
Szymanski, KA ;
Gilmore, JA ;
Tollefson, GD .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (04) :231-238